ARTICLE | Emerging Company Profile
Deep Longevity: Insilico spinout clocks biological age
Deep Longevity’s biomarkers could be used to measure the efficacy of anti-aging therapeutics
July 22, 2020 8:33 PM UTC
Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical trials and in clinical practice.
Alex Zhavoronkov, founder and CEO of Deep Longevity Inc., said the concept of aging clocks first emerged in a 2013 paper in which University of California Los Angeles professor Steve Horvath showed DNA methylation levels correlate with chronological age...